Shares of Voyager Therapeutics dropped more than 12 percent as investors reacted negatively to an announcement that Neurocrine Biosciences is terminating a Parkinson’s disease collaboration between the two companies.

Shares of Voyager Therapeutics skyrocketed after the company announced a collaborative deal to develop a gene therapy treatment for Parkinson’s disease with Neurocrine Biosciences.